Central giant cell granuloma (CGCG), formerly called giant cell reparative granuloma, is a non-neoplastic proliferative lesion of an unknown aetiology. It occurs most commonly in the mandible. The ...

giant cell tumor of bone (GCT), aneurysmal bone cyst (ABC), tenosynovial giant cell tumor (TGCT), and giant cell reparative granuloma (GCRG). Results: Immunohistochemical (IHC) analysis reveals strong ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

[5] Bruits may be heard over the carotid or subclavian areas, or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be given to the examination of ...

Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery. Treatment with emactuzumab has received fast ...

3 Department of Medicine, Sunnybrook and Women’s College Health Sciences Centre, Toronto, Ontario, Canada Correspondence to: Dr Joel G Ray Department of Medicine, Inner City Health, St Michael’s ...

The long-term therapy and surveillance of patients with GCA is important. The side effects of long-term steroid therapy are protean and must be addressed. All patients need adequate calcium and ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

[1] Dermoid cyst with giant cell granuloma in the extra conal space of orbit-A rare case report from Odisha ...

Rinvoq is a Key Top-Line Driver for AbbVie Rinvoq is a key top-line driver for AbbVie. The drug generated sales of almost $6 billion in 2024, which was up 50.4% year over year, owing to continuous ...